PDCD1 and melanoma: revealed that CXCL9 (derived from CD103+ dendritic cell) and CD8+ T cells (CXCR3+ are essential for the efficiency of anti-PD-1 therapy in melanoma, colon adenocarcinoma, and breast adenocarcinoma cell lines (21).